This comes about a week after Pfizer came out with news that preliminary data showed its vaccine candidate appears to be 90 per cent effective in stopping transmission of COVID-19 among people who have not been previously infected.
U.S. biotech firm Moderna on Monday announced its experimental vaccine against Covid-19 was nearly 95 percent effective, marking a second major breakthrough in the quest to end the pandemic. Scientists have warned for months that any COVID-19 shot might be only as good as flu vaccines, which are about 50% effective.
"Positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease", says Stephane Bancel, Moderna's CEO..
Other COVID-19 vaccines may come along that work just as well or even better than this new vaccine.
What about the Pfizer vaccine?
Neil Shearing, group chief economist at Capital Economics, wrote in a research note on Monday before the Moderna results were announced that vaccine breakthroughs show "there is finally light at the end of the tunnel".
Moderna has a $1.525 billion contract to provide the United States with 100 million doses of the vaccine through Operation Warp Speed, the government's fast-track program for Covid-19 vaccines, therapeutics, and diagnostics.
Trudeau called news of Pfizer's promising trials "very encouraging" on November 9, but added other vaccine candidates have also appeared to progress well. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group.
"The maximum effectiveness of the vaccine was observed seven days after the second dose".
"We also have ethicists on this group to help us make sure that it's distributed fairly and equitably, to those who absolutely need it most", she said. Under normal refrigeration temperatures of 36-46 degrees, it can last for up to 30 days.
‘Grey’s Anatomy’: Krista Vernoff & Ellen Pompeo React After Season 17 Premiere Reveals
But our effort is nothing compared to the jobs of our leading health workers who are dedicated this season. Likewise, Dempsey told the outlet that he's down to continue to appear on the show.
"Now we have two vaccines that are really quite effective".
All that being said, that efficacy rating was determined after examining only 95 participants in the vaccine study-that's out of 30,000 participants.
The U.S. government doled out $483 million to support Moderna's vaccine development.
The vaccine is already being mass-produced and thousands of doses will be ready to ship following authorization.
The agreement with Moderna has passed the exploratory talks stage with the aim of sealing a deal to get around 160m doses for member states.
The 95 cases included 15 adults aged 65 or over, and 20 participants from diverse communities including 12 people who identified as Hispanic, 4 Black Americans, 3 Asian Americans and 1 person who was multiracial. "It's going to require many vaccines" to meet the global demand, he added. A significant proportion of volunteers, however, experienced more severe aches and pains after taking the second dose, including about 10 percent who had fatigue severe enough to interfere with daily activities while another 9 percent had severe body aches.
Federal and provincial health authorities are also working directly with Pfizer on the logistics of vaccine delivery, the company said. Both the Moderna and Pfizer shots are frozen, but at different temperatures.
Moderna also said it will use its data to seek authorisation in Europe and other regions.
"The results of this trial are truly striking", said Dr.